Anthropic Adds Novartis CEO Vas Narasimhan to Its Board, and That’s a Bigger Deal Than It Sounds

Anthropic just announced that Vas Narasimhan, the CEO of Novartis, is joining its board of directors. He was appointed by the company’s Long-Term Benefit Trust, not by shareholders — and that distinction matters more than most people realize.

Narasimhan is a physician-scientist who’s been running one of the world’s largest pharmaceutical companies. Under his watch, Novartis has gotten more than 35 novel medicines approved. That’s a staggering number in an industry where regulatory hurdles make tech look like the Wild West. Daniela Amodei put it well: “Getting powerful new technology to people safely and at scale is what we think about every day at Anthropic. Vas has been doing exactly that for years.”

Here’s the part that caught my attention. With this appointment, the Trust-appointed directors now hold a majority on Anthropic’s board. The Trust is that weird governance mechanism Anthropic set up where members have zero financial stake in the company. Their only job is to make sure Anthropic doesn’t go full profit-at-all-costs mode. It’s a structure I’ve been skeptical about — corporate governance gimmicks usually don’t survive contact with real money — but this move suggests they’re taking it seriously.

Narasimhan isn’t just another pharma exec. Early in his career, he worked on HIV/AIDS, malaria, and tuberculosis programs in India, Africa, and South America. He’s on the US National Academy of Medicine. He’s chaired the Pharmaceutical Research and Manufacturers of America. The guy has seen how technology interacts with regulation, public health, and global inequality firsthand. That’s exactly the kind of perspective you want when you’re building AI that could reshape healthcare.

Anthropic’s board now includes Dario and Daniela Amodei, Yasmin Razavi, Jay Kreps, Reed Hastings, Chris Liddell, and Narasimhan. It’s a solid group, but Narasimhan brings something the others don’t: experience navigating the most regulated industry on earth while still pushing innovation. AI companies are going to face increasing scrutiny, especially in healthcare applications. Having someone who’s been through FDA approvals, pricing debates, and access controversies is practical, not just symbolic.

I’ll be honest — I was worried Anthropic’s Long-Term Benefit Trust would end up being a PR prop. But giving it majority board control and recruiting someone with Narasimhan’s credibility suggests they actually mean it. Whether that holds up when the pressure hits is another question, but for now, this is one of the more interesting governance moves I’ve seen in AI.